Alx Oncology Holdings (ALXO) EBT (2019 - 2026)

Alx Oncology Holdings has reported EBT for 8 years, with the latest figure at -$21.6 million in Q1 2026.

• Quarterly EBT rose 29.68% year-over-year to -$21.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$95.7 million (up 27.86% YoY) and the FY2025 annual result came in at -$497000.0, up 99.63% from the prior year.
• EBT rose to -$21.6 million in Q1 2026 per ALXO's latest filing, from -$22.8 million in the prior quarter.
• Over five years, EBT peaked at -$21.6 million in Q1 2026 and troughed at -$51.0 million in Q3 2023.
• A 5-year average of -$32.9 million and a median of -$30.7 million in 2025 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2024: EBT plunged 1555.03% in 2022, then surged 39.77% in 2024.
• Over 5 years, EBT stood at -$30.6 million in 2022, then slumped by 49.01% to -$45.7 million in 2023, then jumped by 36.11% to -$29.2 million in 2024, then increased by 21.74% to -$22.8 million in 2025, then rose by 5.3% to -$21.6 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$21.6 million, -$22.8 million, and -$22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.